North America dominates with ~45% share, while Asia Pacific sees fastest expansion; growth driven by BTK inhibitors, BCL-2 drugs like venetoclax, CAR‑T therapies such as Breyanzi, and FDA approvals for pirtobrutinib, zanubrutinib, and acalabrutinib. https://www.datamintelligence.com/research-report/chronic-lymphocytic-leukemia-therapeutics-market?dr